| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.0096 | 1 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | -0.0017 | 1 |